ROCKVILLE, Md. -- Type 2 diabetes drugs aiming to pass FDA muster should be required to consider long-term cardiovascular safety as part of the approval mix, according to agency advisers.
safety assessmentFDA Advisers Call for Cardiovascular-Safety Assessment of New Di...MedPage Today Infectious Disease Thu, 07/03/2008 - 10:37
|
